C4 Therapeutics, Inc.

Hoffmann-la Roche Inc.

C4 Therepeutics, Inc.

F. Hoffmann-la Roche Ag

Philipp Schmid

Roger David Norcross

Christopher G Nasveschuk

Bernd Kuhn

Rainer Eugen Martin

Fabian Dey

Annick Goergler

Guido Galley

Stephan Roever

Philippe Pflieger

Fionn O'Hara

Giuseppe Cecere

Carsten Kroll

Martin Ritter

Eric Andre Kusznir

Uwe Grether

Hans Richter

Alina Tirla

Benoit Hornsperger

Joerg Benz

The present invention provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.

Spirocyclic compounds

The present invention provides selected glutarimides which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.

Glutarimides for medical treatment

The present invention provides compounds and intermediates. The present invention also provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.

The present invention relates to compounds TAAR receptor antagonists of formula I wherein X, R, L, Ar and Rare as described herein, compositions containing compounds of formula I, methods of manufacture of compounds of formula I and methods of treating psychiatric disorders with compounds of formula I. 

6-amino-5,6,7,8-tetrahydronaphthalen-2-yl or 3-aminochroman-7-yl derivatives

Growing community of inventors

Birsfelden, Switzerland

Philipp Schmid